255 related articles for article (PubMed ID: 18232649)
41. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
Elgazwy AS; Ismail NS; Elzahabi HS
Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
[TBL] [Abstract][Full Text] [Related]
42. Consecutive gold(I)-catalyzed cyclization reactions of o-(buta-1,3-diyn-1-yl-)-substituted N-aryl ureas: a one-pot synthesis of pyrimido[1,6-a]indol-1(2H)-ones and related systems.
Sharp PP; Banwell MG; Renner J; Lohmann K; Willis AC
Org Lett; 2013 Jun; 15(11):2616-9. PubMed ID: 23692341
[TBL] [Abstract][Full Text] [Related]
43. Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
Lee S; Lee H; Kim J; Lee S; Kim SJ; Choi BS; Hong SS; Hong S
J Med Chem; 2014 Aug; 57(15):6428-43. PubMed ID: 25004409
[TBL] [Abstract][Full Text] [Related]
44. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and biological evaluation of 7-azaisoindigo derivatives.
Wang ZH; Wang T; Yao SN; Chen JC; Hua WY; Yao QZ
Arch Pharm (Weinheim); 2010 Mar; 343(3):160-6. PubMed ID: 20186868
[TBL] [Abstract][Full Text] [Related]
46. [Synthesis and antitumor activities of pyrimidines].
You WW; Zhao PL; Zou M; Zhou ZZ; Duan AN; Wu SG
Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):875-7. PubMed ID: 21602147
[TBL] [Abstract][Full Text] [Related]
47. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.
Fancelli D; Berta D; Bindi S; Cameron A; Cappella P; Carpinelli P; Catana C; Forte B; Giordano P; Giorgini ML; Mantegani S; Marsiglio A; Meroni M; Moll J; Pittalà V; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Varasi M; Vulpetti A; Vianello P
J Med Chem; 2005 Apr; 48(8):3080-4. PubMed ID: 15828847
[TBL] [Abstract][Full Text] [Related]
48. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.
Ahn YM; Vogeti L; Liu CJ; Santhapuram HK; White JM; Vasandani V; Mitscher LA; Lushington GH; Hanson PR; Powell DR; Himes RH; Roby KF; Ye Q; Georg GI
Bioorg Med Chem; 2007 Jan; 15(2):702-13. PubMed ID: 17123821
[TBL] [Abstract][Full Text] [Related]
50. Intercalative DNA binding of the marine anticancer drug variolin B.
Canals A; Arribas-Bosacoma R; Albericio F; Álvarez M; Aymamí J; Coll M
Sci Rep; 2017 Jan; 7():39680. PubMed ID: 28051169
[TBL] [Abstract][Full Text] [Related]
51. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
52. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
53. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
55. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
[TBL] [Abstract][Full Text] [Related]
56. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
[TBL] [Abstract][Full Text] [Related]
57. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Sutherlin DP; Bao L; Berry M; Castanedo G; Chuckowree I; Dotson J; Folks A; Friedman L; Goldsmith R; Gunzner J; Heffron T; Lesnick J; Lewis C; Mathieu S; Murray J; Nonomiya J; Pang J; Pegg N; Prior WW; Rouge L; Salphati L; Sampath D; Tian Q; Tsui V; Wan NC; Wang S; Wei B; Wiesmann C; Wu P; Zhu BY; Olivero A
J Med Chem; 2011 Nov; 54(21):7579-87. PubMed ID: 21981714
[TBL] [Abstract][Full Text] [Related]
59. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl heterocycles.
El-Sawy ER; Mandour AH; Mahmoud K; Islam IE; Abo-Salem HM
Acta Pharm; 2012 Jun; 62(2):157-79. PubMed ID: 22750815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]